With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

In a shift away from GMOS, aka genetically modified organisms, important research is continuing in gene editing, sometimes ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Gene editing tools like CRISPR/Cas-9 molecular scissors are delivered ... Casgevy enables CRISPR/Cas-9 to edit the BCL11A gene in stem cells to produce fetal hemoglobin. The edited genes are infused ...

Establishment and robust expansion of human fetal brain organoids ... Cas12a represents the next generation of gene editing. Here, the authors present the generation and validation of a Cas12a ...

New gene therapies could transform sickle cell treatment forever. A future without pain crises or hospitalizations may finally be within reach.

Cutting-edge editing techniques are accelerating efforts to create high-yield, resilient varieties of major agricultural products.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204 , an investigational ...